ChemT Biotechnology raised $4 M Seed funding to develop AI intelligence layer for biomanufacturing

With assistance from Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator, Singapore-based ChemT Biotechnology, an AI-driven biotechnology startup, has closed a $4 million seed round led by Wavemaker Ventures and co-investment partner SEEDS, a division of SG Growth Capital.

ChemT Biotechnology said in a statement on Monday that CelMo, an AI-driven Virtual Cell platform trained on billions to trillions of proprietary biological sequencing reads and proven in the lab, can directly incorporate intelligence into the biomanufacturing process. In order to create a dynamic picture of cell behavior throughout manufacturing, the platform tracks biological processes like growth, metabolism, and stress response while simulating how cells react to manufacturing environments, genetic alterations, and pressures.

The funding, according to Jie Sun, co-founder and CEO of ChemT Biotechnology, validates the company’s team and technology during a challenging funding environment for life sciences. He noted that within about a year and a half of launch, ChemT has established commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies worldwide.

The funding will promote the growth of ChemT Biotechnology’s AI and experimental infrastructure, the advancement of its molecular products toward GMP standards, and the expansion of CelMo into stem cells, NK cells, and HEK cells in addition to CHO and T cells.

The lack of computational knowledge of cellular networks has long limited biomanufacturing, according to Paul Santos, co-founder and managing partner of Wavemaker Partners. ChemT’s precision small molecules provide manufacturers with a new lever for quicker, more affordable, and higher-yield production.